3
Announcements
Trials
Browse
Landscape
Phase
Phase 1/2
1
Status
Completed
7
Terminated
3
Recruiting
2
Withdrawn
1
Unknown
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Other hematologic neoplasm
1
Conditions
Multiple Myeloma
45
Recurrence
14
Lymphoma
6
Neoplasms
5
Neoplasms, Plasma Cell
4
Lymphoma, Large B-Cell, Diffuse
4
Waldenstrom Macroglobulinemia
2
Precursor Cell Lymphoblastic Leukemia-Lymphoma
2
Lymphoma, Mantle-Cell
2
Lymphoma, Follicular
2
Lymphoma, B-Cell, Marginal Zone
2
Lung Neoplasms
2
Leukemia, Lymphocytic, Chronic, B-Cell
2
Immunoglobulin Light-chain Amyloidosis
2
Hodgkin Disease
2
Glioblastoma
2
Amyloidosis
2
Wilms Tumor
1
Vomiting
1
Small Cell Lung Carcinoma
1
Sarcoma
1
Prostatic Neoplasms
1
Precursor T-Cell Lymphoblastic Leukemia-Lymphoma
1
Polycystic Ovary Syndrome
1
Ototoxicity
1
Osteosarcoma
1
Obesity
1
Neoplasms, Germ Cell and Embryonal
1
Neoplasm, Residual
1
Neoplasm Metastasis
1
Interventions
fludarabine
6
Cyclophosphamide
5
fludarabine phosphate
4
Whole-Body Irradiation
4
itacitinib
3
angiotensin I (1-7)
3
pembrolizumab
2
Tacrolimus
2
Olanzapine
2
Nivolumab
2
Magnetic Resonance Spectroscopy
2
Ipilimumab
2
INCB039110
2
CTLA-4 Antigen
2
Busulfan
2
Brentuximab Vedotin
2
Bendamustine Hydrochloride
2
AP 1903 reagent
2
tazemetostat
1
tafasitamab
1
ruxolitinib
1
pomalidomide
1
ofatumumab
1
merphos
1
lopinavir-ritonavir drug combination
1
ivosidenib
1
ibrutinib
1
fedratinib
1
enasidenib
1
daratumumab
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Withdrawn
×
Hematologic Neoplasms
×
Dexamethasone
×
Clear all
NCT05205252
2023-08-15
ARIA
Ipsen
Phase 1/2
Withdrawn